How Could EMA's Elfabrio Decision Reshape Protalix BioTherapeutics' (PLX) Rare Disease Strategy?

Simply Wall St.

2025/10/20

Earlier in October 2025, Protalix BioTherapeutics and Chiesi Group received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2577866044"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577866044\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577866044?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-10-20 21:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577866044","market":"nz","top_or_hot":-1,"title":"How Could EMA's Elfabrio Decision Reshape Protalix BioTherapeutics' (PLX) Rare Disease Strategy?","media":"Simply Wall St.","content":"<div>\n<p>Earlier in October 2025, Protalix BioTherapeutics and Chiesi Group received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/news/how-could-emas-elfabrio-decision-reshape-protalix-biotherape\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Could EMA's Elfabrio Decision Reshape Protalix BioTherapeutics' (PLX) Rare Disease Strategy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Could EMA's Elfabrio Decision Reshape Protalix BioTherapeutics' (PLX) Rare Disease Strategy?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2025-10-20 21:16</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Earlier in October 2025, Protalix BioTherapeutics and Chiesi Group received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/news/how-could-emas-elfabrio-decision-reshape-protalix-biotherape\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/news/how-could-emas-elfabrio-decision-reshape-protalix-biotherape\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4087","symbol_name":"商業印刷","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/news/how-could-emas-elfabrio-decision-reshape-protalix-biotherape","article_id":"2577866044","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/news/how-could-emas-elfabrio-decision-reshape-protalix-biotherape","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2577866044","pubTimestamp":1760966206,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier in October 2025, Protalix BioTherapeutics and Chiesi Group received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding Elfabrio’s proposed less-frequent dosing regimen for Fabry disease, as the data was considered insufficient to demonstrate similar efficacy to the currently approved schedule.\nThis regulatory decision highlights ongoing challenges in achieving flexibility for rare disease treatments, with...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4087":"商业印刷","BK4081":"电力公用事业","CHMP":"冠军工业","EMA":"Emera Inc.","PLX":"Protalix BioTherapeutics Inc","BK4139":"生物科技"},"translate_title":"EMA的Elfabrio决定如何重塑Protalix BioTherapeutics(PLX)的罕见病战略？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMA":1.5,"CHMP":1,"PLX":1.5},"content_text":"Earlier in October 2025, Protalix BioTherapeutics and Chiesi Group received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding Elfabrio’s proposed less-frequent dosing regimen for Fabry disease, as the data was considered insufficient to demonstrate similar efficacy to the currently approved schedule. This regulatory decision highlights ongoing challenges in achieving flexibility for rare disease treatments, with implications for both patient care and future product adoption efforts. We'll assess how the EMA's rejection of Elfabrio's revised dosing impacts the company’s expansion strategy and risk profile. The latest GPUs need a type of rare earth metal called Terbium and there are only 36 companies in the world exploring or producing it. Find the list for free.AdvertisementProtalix BioTherapeutics Investment Narrative RecapOwning shares in Protalix BioTherapeutics today requires confidence in the ongoing commercialization of Elfabrio for Fabry disease, and successful execution of its partnership with Chiesi. The EMA’s recent rejection of the less-frequent Elfabrio dosing does curb a potential near-term growth catalyst, but does not directly threaten the company’s current ability to generate revenue from its already-approved schedule. The most significant immediate risk remains the company’s heavy reliance on this single product and ongoing regulatory approvals. One relevant recent announcement is Protalix’s August 2025 earnings update, which highlighted revenue growth and a return to net profitability in the latest quarter. While this financial improvement reflects the underlying strength of existing Elfabrio sales, the limited label expansion following EMA’s negative opinion could make future revenue visibility more challenging if alternative dosing regimens stay off the table. Yet amid this, investors should also take note that... Read the full narrative on Protalix BioTherapeutics (it's free!)Protalix BioTherapeutics' outlook anticipates $188.6 million in revenue and $132.1 million in earnings by 2028. This scenario assumes a 44.9% annual revenue growth rate and a $125.8 million increase in earnings from the current $6.3 million.Uncover how Protalix BioTherapeutics' forecasts yield a $14.00 fair value, a 653% upside to its current price.Exploring Other PerspectivesPLX Community Fair Values as at Oct 2025 Simply Wall St Community members provided 8 fair value estimates for Protalix, ranging from US$3.68 to US$16.37 per share. Against this backdrop of widely differing expectations, the company’s dependence on Elfabrio for sales growth means any regulatory hurdles can have an outsized impact, be sure to consider all the perspectives before making your own assessment.Explore 8 other fair value estimates on Protalix BioTherapeutics - why the stock might be worth just $3.68!Build Your Own Protalix BioTherapeutics NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Protalix BioTherapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Protalix BioTherapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Protalix BioTherapeutics' overall financial health at a glance.Looking For Alternative Opportunities?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Uncover the next big thing with financially sound penny stocks that balance risk and reward.The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}